RSS

The Memorial Sloan Kettering Cancer Center

Aprea Therapeutics, Karolinska Development’s portfolio company, has announced a collaboration with Memorial Sloan Kettering Cancer Center to study the effects of reactivation of tumour suppressor protein p53 by APR-246. more

News

The Memorial Sloan Kettering Cancer Center has opted to use PDS Life Sciences' Ascentos software suite to manage and analyse data that will be generated in its new GLP-compliant preclinical research laboratories. more

Technology